NVCT

Over the past six months, Nuvectis Pharma's stock increased by 54.3% from $7.55 to $11.65, with a 52-week trading range between $5.55 and $11.15. Key events include the company reporting a net loss of $6.1 million in Q1 2026, insider stock buying reaching US$2.07 million, a price target decrease of 11.71% to $16.66, presentations for NXP900 at the 2026 AACR Meeting, initiation of the Phase 1b study of NXP900 in combination with Osimertinib in patients with NSCLC, and hosting a virtual Key Opinion Leader meeting to discuss the NXP900 Phase 1b program. A new minor risk of shareholder dilution was identified in May 2026, with an 18% increase in shares outstanding over the past year.